Literature DB >> 9257853

DNA vaccines against lymphoma: promotion of anti-idiotypic antibody responses induced by single chain Fv genes by fusion to tetanus toxin fragment C.

M B Spellerberg1, D Zhu, A Thompsett, C A King, T J Hamblin, F K Stevenson.   

Abstract

Idiotypic determinants can act as tumor-associated Ags for B cell lymphoma. Vaccination with idiotypic protein and adjuvant is known to induce specific protection against lymphoma challenge in mice, largely mediated by anti-idiotypic Ab. For facilitating the approach for patients, the V(H) and V(L) genes used to encode the individual idiotypic determinants of each tumor can be obtained by PCR and assembled as single chain Fv (scFv). DNA vaccines containing scFv sequences alone induce low and poorly reproducible levels of anti-idiotypic Ab, likely to be insufficient to suppress tumor in patients. In addition, it may be necessary to break tolerance to Id in tumor bearers. By fusing the gene for fragment C of tetanus toxin to the C terminus of human scFv, we have promoted the anti-scFv Ab response in mice by >50-fold in three of three cases. The induced Abs are mainly against idiotypic determinants, and react specifically with patients' tumor cells, indicating optimal folding of the scFv molecule in the fusion protein. For both antigenic components of the DNA vaccine, the IgG subclass distribution showed a relative increase in IgG2a as compared with vaccination with IgM protein in adjuvant. In patients, the fusion gene should both promote anti-idiotypic Ab and induce Abs against fragment C of tetanus toxin. The latter response would provide a potentially useful comparative measure of the ability of patients to respond to conventional Ag delivered via DNA.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9257853

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

Review 1.  Vaccination strategies for lymphomas.

Authors:  Mohammed M Dar; Larry W Kwak
Journal:  Curr Oncol Rep       Date:  2003-09       Impact factor: 5.075

2.  Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants.

Authors:  A A McCormick; M H Kumagai; K Hanley; T H Turpen; I Hakim; L K Grill; D Tusé; S Levy; R Levy
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-19       Impact factor: 11.205

3.  Inhibition of a vaccine-induced anti-tumor B cell response by soluble protein antigen in the absence of continuing T cell help.

Authors:  Natalia Savelyeva; Catherine A King; Ellen S Vitetta; Freda K Stevenson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-21       Impact factor: 11.205

4.  Insight into the potential for DNA idiotypic fusion vaccines designed for patients by analysing xenogeneic anti-idiotypic antibody responses.

Authors:  Francesco Forconi; Catherine A King; Surinder S Sahota; Christopher K Kennaway; Nigel H Russell; Freda K Stevenson
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

5.  Genetic immunization with CDR3-based fusion vaccine confers protection and long-term tumor-free survival in a mouse model of lymphoma.

Authors:  Sandra Iurescia; Daniela Fioretti; Pasquale Pierimarchi; Emanuela Signori; Manuela Zonfrillo; Giancarlo Tonon; Vito M Fazio; Monica Rinaldi
Journal:  J Biomed Biotechnol       Date:  2010-04-27

6.  Enhancement of DNA vaccine potency through linkage of antigen to filamentous bacteriophage coat protein III domain I.

Authors:  Angel M Cuesta; Eduardo Suárez; Martin Larsen; Kim Bak Jensen; Laura Sanz; Marta Compte; Peter Kristensen; Luis Alvarez-Vallina
Journal:  Immunology       Date:  2006-04       Impact factor: 7.397

7.  Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase I clinical study.

Authors:  A A McCormick; S Reddy; S J Reinl; T I Cameron; D K Czerwinkski; F Vojdani; K M Hanley; S J Garger; E L White; J Novak; J Barrett; R B Holtz; D Tusé; R Levy
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-21       Impact factor: 11.205

Review 8.  DNA vaccines to attack cancer.

Authors:  Freda K Stevenson; Christian H Ottensmeier; Peter Johnson; Delin Zhu; Sarah L Buchan; Katy J McCann; Joanne S Roddick; Andrew T King; Feargal McNicholl; Natalia Savelyeva; Jason Rice
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-03       Impact factor: 11.205

9.  scFv6.C4 DNA vaccine with fragment C of tetanus toxin increases protective immunity against CEA-expressing tumor.

Authors:  Anjali Geethadevi; Kapilesh Jadhav; Gaurav Kumar; Deepak Parashar
Journal:  Gene Ther       Date:  2020-06-01       Impact factor: 5.250

Review 10.  Therapeutic cancer vaccines: past, present, and future.

Authors:  Chunqing Guo; Masoud H Manjili; John R Subjeck; Devanand Sarkar; Paul B Fisher; Xiang-Yang Wang
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.